ArticleFrontiers in genetics2026
Clinical and neuropsychological profile of Alzheimer's disease in Tunisia and the impact of
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD), the leading cause of major neurocognitive disorder (MNCD) worldwide and in Tunisia, is strongly associated with Apolipoprotein E ( Methods: We included patients with a clinical diagnosis of probable or possible AD, who consulted in the Department of Neurology at Razi University Hospital over a span of 21 years. Demographic, clinical, and neuropsychological data were assessed. Results: Among 1,010 AD patients, the sex ratio was 0.62, with a mean age at onset of 68.9 ± 9.8 years. Consanguinity was reported in 30.2% of cases, and a family history of major neurocognitive disorder in 65.3%. The mean Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) scores were 14.1 ± 7.7 and 6.5 ± 4.8, respectively. Overall, 47.0% of patients carried the Discussion: The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.